Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Invested Capital (2016 - 2025)

Integra Lifesciences Holdings' Invested Capital history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Invested Capital fell 23.23% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, down 23.23%, while the annual FY2025 figure was $1.8 billion, 23.23% down from the prior year.
  • Invested Capital for Q4 2025 was $1.8 billion at Integra Lifesciences Holdings, roughly flat from $1.8 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $2.6 billion in Q4 2022 and bottomed at $1.8 billion in Q4 2025.
  • The 5-year median for Invested Capital is $2.4 billion (2021), against an average of $2.3 billion.
  • The largest annual shift saw Invested Capital grew 9.64% in 2021 before it dropped 23.23% in 2025.
  • A 5-year view of Invested Capital shows it stood at $2.5 billion in 2021, then rose by 2.01% to $2.6 billion in 2022, then decreased by 8.39% to $2.4 billion in 2023, then fell by 2.42% to $2.3 billion in 2024, then decreased by 23.23% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Invested Capital are $1.8 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.8 billion (Q2 2025).